- Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
For: Hodgkin LymphomaUnited States · Brazil · Colombia - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium - RecruitingPHASE2
Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
This study is looking at a new medicine called Trametinib for children and young adults with a specific type of slow-growing brain tumour called low-grade glioma. It compares Trametinib to a standard treatment, Vinblastine, to see if it works better at stopping the tumour from growing.
For: Grade 1 Glioma · Mixed Glio-neuronal Tumors · Pleomorphic XanthoastrocytomaFrance - RecruitingEARLY_PHASE1
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
This study looks at a new combination of two medicines, tovorafenib and vinblastine, for children and young adults (up to 25) with a type of brain tumour called low-grade glioma. It focuses on tumours with specific genetic changes.
For: Low-grade GliomaCanada - Active not recruitingPHASE1, PHASE2
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
This study looks at a new drug, Nivolumab, combined with standard treatment (ABVD) for Hodgkin lymphoma. The goal is to improve the chances of a cure, especially for people with higher-risk forms of the disease. It checks if adding Nivolumab helps when initial treatment doesn't fully clear the cancer.
For: Hodgkin LymphomaUnited States · Canada - RecruitingPHASE3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
This study, called NIAGARA-2, is looking at a new way to treat bladder cancer that has grown into the muscle. It combines a drug called durvalumab with standard chemotherapy, given before and after surgery. The aim is to see if this combination improves treatment.
For: Urinary Bladder Neoplasms · Immune Checkpoint Inhibitors · MethotrexateAustralia · Brazil · Canada